Clinical Trial Update: Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating de-escalation of Pd-103 brachytherapy dosing in early-stage prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Palladium-103 brachytherapy (Palladium-103)

Snippet

Sponsor: Schiffler Cancer Center | Conditions: Prostatic Neoplasm | Phase 3 | Status: COMPLETED